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Abstract To further clarify the complex transcriptional regula-
tion of the human GM-CSF gene, which was extensively 
investigated in activated T cells, we have studied the role of an 
upstream N F - K B like site in the 5637 non-lymphoid cell line, 
which derives from a bladder carcinoma and constitutively 
produces GM-CSF. This sequence, named the A element, has an 
active role on GM-CSF transcription and is responsive to the 
tumor promoter PMA in transient transfection experiments. We 
describe here a heterodimeric binding complex of N F - K B 
subunits (c-Rel and p65) which is identical to the one obtained 
using the H I V - L T R - K B site as recognition sequence and 
different from the one (c-Rel and p50) observed with nuclear 
extracts from Mo T-lymphoid HTLV-II infected cells. 
© 1997 Federation of European Biochemical Societies. 
Key words: Nuclear factor K B ; 
Granulocyte macrophage-colony stimulating factor; 
Phorbol 12-myristate 13-acetate; Transcriptional regulation 
1. Introduction 
G M - C S F is a glycoprotein cytokine involved in hematopoi-
esis and host defense [1]. With regard to the transcriptional 
control of G M - C S F gene expression, a distal and a proximal 
promoter region have been investigated. The first contains an 
enhancer located approximately 3 kb upstream of the tran-
scriptional start site [2], and the second, spanning at least the 
first 120 bp from the transcriptional start site, includes recog-
nition sites for the binding of several constitutive and indu-
cible nuclear proteins which contribute to the transcriptional 
regulation of the G M - C S F gene [3,4]. These proximal ele-
ments include two binding sites for the NF-KB/Rel family of 
transcription factors (the K B element which binds the classical 
p65-p50 complex and the CK1 element which binds p65-c-
Rel) [5-7]. 
Several reports describe the central role played by the K B 
element in the response of the G M - C S F promoter to T cell 
receptor type signals as well as to Tax activation in T cells 
[4,8] and, up to now, studies on these N F - K B sites have fo-
cused on activated T cells. 
We previously identified a novel upstream K B element, 
within a sequence, defined the A element, located between 
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- 2 0 0 2 and - 1 9 8 4 [9], which binds members of the N F - K B 
family. This sequence is active as a positive transcriptional 
element in the G M - C S F producing lymphoblastoid cell line 
Mo, HTLV-II infected and expressing the Tax protein [10]. 
We also observed a similar positive transcriptional role of the 
A element, although weaker in quantity, in a cell line of differ-
ent origin, the 5637 bladder carcinoma cells [9], which con-
stitutively produce G M - C S F [11]. 
Here, we describe the A element binding complex, which 
differs for subunit composition from the one previously ob-
served in the human T cell leukemia M o cell line, in nuclear 
extracts of 5637 cells, prepared from untreated cells and from 
stimulated cells with the tumor promoter PMA, the action of 
which mimics Tax activation by stimulating N F - K B [12,13]. 
Our data provide evidence that N F - K B family members 
acting on the G M - C S F promoter associate differently in a 
tissue specific and activation dependent manner. 
2. Materials and methods 
2.1. Cell culture and induction conditions 
The 5637 cell line, derived from a human bladder carcinoma and 
constitutively producing GM-CSF, was cultured in DMEM supple-
mented with 10% fetal calf serum, penicillin and streptomycin in a 
humidified atmosphere with 5% CO2. When stimulated, the cells were 
incubated with 50 ng/ml of PMA for 4, 8 and 24 h prior to harvesting. 
The Mo cell line, originally obtained from the American Type Culture 
Collection, was cultured in Iscove's modified Dulbecco's medium sup-
plemented with 10% fetal calf serum, penicillin and streptomycin in a 
humidified atmosphere with 5%> CO2. 
2.2. Plasmids and transfections 
Plasmids used for transfections were all prepared in our laboratory: 
PF2000, containing the first 2010 bp upstream of the transcription 
start site of the GM-CSF gene, was prepared by subcloning from a 
phagic clone, and PF20 and PF24, containing respectively the first 
1742 and 240 bp of the 5' flanking sequence upstream of the tran-
scription start site were derived from PF2000, as described [14]. PAA, 
deleted of the KB sequence (A element) between —2002 and —1984, 
was also derived from PF2000, as described [9]. 
Transfections were performed as described [9] using 10 ug of plas-
mid PF 2000 and equimolar amounts of the other constructs (for all 
constructs, at least two different plasmid preparations were used), 
together with 5 ag of pRSV-bgal as an internal control. Extracts 
were prepared from unstimulated or PMA stimulated cells for CAT 
activity assay, which was measured by standard methods [15]. The 
values of CAT activity were corrected for protein concentration and 
for p-galactosidase activity to normalize variability in transfection 
efficiency. Mo cells were electroporated as previously described [9]. 
Relative CAT activities (mean ± S.E.M.) were calculated from at least 
three unrelated experiments (performed in duplicate) by using PF2000 
plasmid transfected in unstimulated cells as a reference value in all 
experiments. The magnitude of induction in response to PMA was 
calculated relative to the unstimulated cells for every construct. 
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2.3. Preparation of cellular and nuclear extracts 
Cells, unstimulated and stimulated with PMA for 4, 8 and 24 h, 
were lysed in RIPA buffer (IXphosphate buffer saline, 1% NP40, 
0.5% sodium deoxycholate, 0.1% SDS, 0.5 mM phenylmethylsulfonyl 
fluoride). After 30 min at 4°C the mixture was centrifuged at 14000 
rpm for 15 min and the supernatant was treated as whole cell extract 
for Western blot. 
Nuclear extracts, from unstimulated cells or after stimulation for 8 h 
with PMA, were prepared according to the method of Dignam [16]. 
All steps were carried out at +4°C, in the presence of phenylmethyl-
sulfonyl fluoride (0.5 mM). The nuclear extracts were dialyzed against 
a buffer containing 12.5 mM HEPES (pH 7.9), 100 mM NaCl, 0.2 
mM EDTA, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl 
fluoride and 10% glycerol to bring the samples to optimal buffer 
and salt conditions for binding in EMSA, aliquoted and stored at 
-80°C. 
2.4. Western blot analysis 
5637 cellular extracts were subjected to SDS-PAGE (10% polyacry-
lamide) and Western blot analysis according to a previously described 
procedure [17]. Chemiluminescent detection was carried out according 
to the manufacturer's specifications (ECL Western blotting detection 
system, Amersham), using peroxidase conjugated antirabbit Ig 
(1:10000). Antibodies, recognizing members of the NF-KB family, 
were: anti-c-Rel (sc-71x), anti-RelA (sc-109x), anti-p50 (sc-1190x) 
used at 1:5000 dilution, all purchased from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA. 
2.5. Electrophoretic mobility shift assay (EMSA) 
For binding assay, double stranded oligonucleotides corresponding 
to the A element in the GM-CSF promoter 5'-TCCTCAGCTCTG-
GACTTCCCCCT-3' (upper strand) [9] and to the NF-KB motif 
present in the HIV-LTR (5'-GTAGGGGACTTTCCGAGCTCGA-
GATCCTATG-3', upper strand) [18] were used as [32P] labeled 
probes or as unlabeled competitors. 
The assays were performed as previously described [9]: nuclear ex-
tracts of 5637 cells (3 ug), both unstimulated and stimulated for 8 h 
with PMA, or 1 ug of Mo nuclear extract, were pre-incubated in a 15 
ul incubation mixture containing 12.5 mM HEPES (pH 7.9), 100 mM 
NaCl, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 
10%o glycerol and 4 ug of poly (dl-dC) as a non-specific competitor for 
10 min at room temperature. End-labeled oligonucleotides (5 fmol, 
about 10000 cpm) were added to each reaction mixture and incubated 
for an additional 15 min. The bound complexes were separated from 
free probe by electrophoresis on 5%> polyacrylamide gels. Complexes 
were visualized by autoradiography of the dried gels. 
Competition experiments were performed in the presence of a 50-, 
100-, or 500-fold molar excess of unlabeled HIV-NF-KB or A oligo-
nucleotide. 
For supershift assay, 1 ug of c-Rel, p65 or p50 antibody was in-
cluded in the pre-incubation mixture prior to the addition of the 
probe and loading onto polyacrylamide gels, and a lane containing 
pre-immune serum was always included as control. 
3. Results and discussion 
3.1. The A element participates in response to PMA 
stimulation in 5637 cells 
PMA has been reported to stimulate GM-CSF promoter 
activity in Jurkat and MLA144 cell lines in transient trans-
fection assay with a 193 bp promoter fragment immediately 
upstream of the transcription start site [19]. Since this frag-
ment contains responsive KB recognition sites [5-7], we have 
investigated the role of the upstream A element, also contain-
ing a KB site [9], on PMA mediated regulation in 5637 cells. 
The transcriptional effect of PMA on the KB element be-
tween — 1984 and —2002 was verified by transfecting PF2000, 
PAA, PF20 and PF24 plasmids in both uninduced and PMA-
induced 5637 cells. Transfections showed a 3.4-fold stimula-
tion of pPF2000 compared with uninduced level, while only a 
slight increase was obtained with pAA (1.5-fold), a construct 
Fig. 1. Activation of the GM-CSF promoter by PMA in 5637 cells. 
Results of CAT assay (mean±S.E.M. of four experiments per-
formed in duplicate) are represented with grey bars for cells in basal 
conditions and dark bars for cells stimulated with PMA. Induction 
by PMA is expressed as fold stimulation relative to unstimulated 
cells. CAT activity of PF2000 in unstimulated cells was set to one 
and all other values were related to it. 
deleted of the KB site, and with further deleted promoter 
constructs (1.9-fold for p20 and 1.6-fold for p24), as described 
in Fig. 1. In a preliminary subset of experiments we did not 
observe a significant stimulatory effect of PMA on T-lym-
phoid Mo cells transfected with all plasmid constructions 
(data not shown). 
Therefore, we started to investigate PMA action on N F - K B 
family members binding to the A element in 5637 cells. 
3.2. NF-KB members binding to the A element are induced by 
PMA stimulation 
Optimal N F - K B subunit induction by phorbol ester was 
ascertained by a preliminary Western blot analysis of extracts 
from 5637 cells, both untreated and after stimulation for 4, 8, 
and 24 h. Treatment with PMA resulted in an increase of the 
endogenous p65 and c-Rel levels which peaked at 8 h and 
declined thereafter (Fig. 2). This time was chosen as the opti-
mal time of stimulation, and nuclear extracts of cells treated 
for 8 h were used for EMSA and supershift analyses. 
3.3. c-Rel and p65 subunits bind to the A element and to the 
HIV-NF-KB site 
Gel shift analysis with the A element used as a labeled 
probe demonstrated induction of a binding complex showing 
two major bands, different from the one detected with Mo 
nuclear extracts (Fig. 3A). This complex showed an increased 
intensity in the nuclear extracts from PMA stimulated cells 
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Fig. 2. Western blot analysis of 5637 cellular extracts using anti-p65 
(lanes 1^ 1) and anti-c-Rel (lanes 5-8) antibodies. Extracts were from 
cells both untreated (lanes 1 and 5) and treated for 4 h (lanes 2 and 
6), 8 h (lanes 3 and 7) or 24 h (lanes 4 and 8) with PMA. Molecu-
lar weight markers (kDa) are indicated on the left side. The arrows 
indicate p65 (lanes l^f) and c-Rel (lanes 5-8). 
and was found to be identical also using the KB DNA binding 
motif present in the HIV-LTR as a labeled probe (Fig. 3C). 
Competition experiments (Fig. 3B) showed that the re-
tarded complex observed could be very efficiently competed 
by an excess of the A oligonucleotide itself as well as by the 
H I V - N F - K B oligonucleotide. 
EMSA analysis in presence of specific antibodies defined c-
Rel and p65 as constituents of the complex, since the addition 
of the antibody to the binding mixture led to disappearance 
(with anti-c-Rel) or supershift (with anti-p65) of the retarded 
Fig. 3. EMSA assays showing binding of an NF-KB like complex to 
the A element and to the NF-KB site of HIV. The bands in lanes 
Al and Cl, A2 and C2, A3 and C3 refer to the same substance ob-
tained with two different labeled oligonucleotides. A: The labeled A 
oligonucleotide was incubated with 1 ug of Mo nuclear extract (lane 
1), 3 |xg of 5637 nuclear extract in basal conditions (lane 2), and 
after stimulation for 8 h with PMA (lane 3). B: EMSA with PMA 
stimulated 5637 nuclear extract (3 ug) without competitor (lane 1) 
and in the presence of either a 50-, 100-, and 500-fold molar excess 
of the unlabeled A oligonucleotide as competitor (lanes 2, 3, 4 re-
spectively) or of a 50-, 100-, and 500-fold molar excess of the HIV-
NF-KB competitor (lanes 5, 6, 7 respectively). C: The labeled HIV-
NF-KB oligonucleotide was incubated with 1 ug of Mo nuclear ex-
tract (lane 1), 3 ug of 5637 nuclear extract in basal conditions (lane 
2), and after stimulation for 8 h with PMA (lane 3). The spot in 
the middle of B4-B5 was due to contamination and has no meaning 
for the experiment. 
Fig. 4. EMSA assays in the presence of specific antibodies. A: 3 |ig 
of 5637 nuclear extracts were incubated with the A oligonucleotide 
as a labeled probe in the presence of pre-immune serum (lane 1), or 
1 |xg of anti-p65 (lane 2), anti-c-Rel (lane 3) and anti-p50 (lane 4). 
B: 1 ug of Mo nuclear extract was incubated with the A oligonu-
cleotide as a labeled probe in the presence of pre-immune serum 
(lane 1), or 1 ug of anti-p65 (lane 2), anti-c-Rel (lane 3) and anti-
p50 (lane 4). 
bands. The anti-p50 antibody caused a much less pronounced 
effect that might be due to cross reaction (Fig. 4A). A virtu-
ally identical pattern was observed when the H I V - L T R - K B 
site was used as labeled probe (data not shown). Nuclear 
extracts from Mo cells were also analysed for comparison. 
The addition of anti-c-Rel to the binding mixture led to super-
shift of the complex, as we previously described [9], anti-p65 
had a minor effect on band intensity and anti-p50 caused a 
significant disappearance of the band (Fig. 4B). The different 
effect of anti-c-Rel, which causes supershift in Mo nuclear 
extracts and band disappearance in 5637, would suggest a 
different composition and/or heterodimerization of the active 
N F - K B subunits. In particular, p65 and c-Rel, detected with 
both the A and the H I V - N F - K B probes, appear as the major 
components of the retarded complex in 5637, whereas in Mo 
cells p50 and c-Rel seem to be the major components. 
The finding that the active N F - K B complexes appear differ-
ent in composition in extracts from Mo cells, which express 
the viral transactivator Tax, if compared with 5637 cells, sup-
ports the idea that KB elements may have distinct regulatory 
properties in different specific contexts and in the presence of 
differential levels of individual subunits [20]. 
It has previously been documented [21] that the gene for 
human GM-CSF is expressed in a tissue specific as well as in 
an activation dependent manner. Our results suggest that the 
upstream A element of the GM-CSF promoter, although rec-
ognized by a KB factor of different subunit composition de-
pending on cell type, is involved in response to different stim-
uli acting through a similar activation pathway. In Mo cells 
the Tax transactivator is likely to be responsible for KB medi-
ated activation of the GM-CSF promoter, while in the 5637 
bladder carcinoma cell line, the tumor promoter PMA has the 
same effect, by acting on the same promoter element through 
an analogous KB mediated activation, probably via phospho-
rylation and degradation of the IKB cytoplasmic inhibitor 
which leads to active N F - K B complexes [12,13]. 
Treatment of 5637 cells with PMA, as has already been 
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described, results in an increase in G M - C S F m R N A [22] and, 
up to now, attention on N F - K B activation by P M A has been 
focused on the proximal promoter region [5,22]. Furthermore, 
the downstream N F - K B sites in G M - C S F promoter have been 
shown to confer strong inducibility upon T cell activation and 
Tax (in T-lymphoid cells) [5]. Little is known about N F - K B 
expression and D N A binding activity in non-lymphoid can-
cers [23]. Our results improve knowledge on the tumor pro-
moter P M A induction in the bladder carcinoma 5637 cells by 
showing the role of the upstream A element. Moreover, we 
show that N F - K B mediated activation of G M - C S F transcrip-
tion is common to lymphoid and non-lymphoid tumor cell 
lines. 
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